| 1 |
NCT03168997 |
Not yet recruiting |
Memantine Treatment in Alzheimer's Disease Patients |
|
- Drug: Memantine Hydrochloride
|
Interventional |
Phase 4 |
- Wei Cuibai
- Xuanwu Hospital, Beijing
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
|
222 |
All |
50 Years and older (Adult, Senior) |
NCT03168997 |
17237T |
|
July 15, 2017 |
September 30, 2018 |
December 31, 2018 |
May 30, 2017 |
May 30, 2017 |
|
|
| 2 |
NCT02208193 |
Unknown † |
Alzheimer's Disease, Art and Garden |
|
- Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Comparaison of the number of language acts in each category between AD and controls subjects
- Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),
- Scores obtained with the " MemoArtZ " tool (MAZ) to evaluate the memorization of artistic elements of the garden,
- (and 3 more...)
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02208193 |
2014-A00139-38 |
JAZ ART |
July 2014 |
October 2016 |
September 2017 |
August 4, 2014 |
July 30, 2015 |
|
|
| 3 |
NCT02947893 |
Recruiting |
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease |
|
- Drug: Placebo Capsule(s) Once a Day by Mouth
- Drug: Nilotinib Capsule(s) Once a Day by Mouth
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values
- Effects of Nilotinib treatment on measurement of Nilotinib in the CSF
|
42 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02947893 |
2016-0315 |
AD |
January 2017 |
February 2019 |
December 2019 |
October 28, 2016 |
February 20, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
| 4 |
NCT02290912 |
Completed |
Gray Matters Alzheimer's Disease Prevention Intervention |
|
- Behavioral: Health education program
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Picture Vocabulary
- Flanker Inhibitory Control and Attention Test
- List Sorting Working Memory Test
- (and 26 more...)
|
146 |
All |
40 Years to 64 Years (Adult) |
NCT02290912 |
5606 |
|
April 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
December 3, 2015 |
|
|
| 5 |
NCT03340571 |
Recruiting |
Blood Biomarker of Alzheimer's Disease (AD) |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological marker of Alzheimer's disease
|
60 |
All |
50 Years and older (Adult, Senior) |
NCT03340571 |
Pro00085997 |
|
March 12, 2018 |
August 2018 |
August 2018 |
November 13, 2017 |
March 14, 2018 |
|
- Duke University
Durham, North Carolina, United States
|
| 6 |
NCT03090854 |
Not yet recruiting |
Cholinergic Markers Alzheimer's Disease |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Neuropsychological test (ADASCog)
- Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
- Difference of CSF Ach AND AChE activity between responder and non responder groups
- Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
|
100 |
All |
50 Years and older (Adult, Senior) |
NCT03090854 |
K160402
2016-AO1639-42 |
CHOLINE |
September 1, 2017 |
September 1, 2019 |
September 1, 2019 |
March 27, 2017 |
August 29, 2017 |
|
- Centre Mémoire de Ressources et de Recherche Paris Nord
Paris, France
|
| 7 |
NCT02253043 |
Recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease |
|
- Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
|
Interventional |
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
- Clinical Dementia Rating Scale
|
10 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02253043 |
PINS-002 |
|
May 2014 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - 301 Hospatl
Beijing, Beijing, China
|
| 8 |
NCT01867372 |
Terminated |
Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes |
|
|
Observational |
|
- National Institute on Aging (NIA)
- Johns Hopkins University
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
|
- Accelerated preclinical changes in brain structure and function in specific regions will predict which individuals develop cognitive impairment and Alzheimer s disease
- Changes in brain structure are predictors of cognitive decline and impairment though neuroimaging assessments
|
213 |
All |
20 Years and older (Adult, Senior) |
NCT01867372 |
999903328
03-AG-N328 |
|
March 10, 2003 |
September 22, 2014 |
September 22, 2014 |
June 4, 2013 |
April 23, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Kennedy Krieger Institute
Baltimore, Maryland, United States - National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States
|
| 9 |
NCT02097056 |
Completed
Has Results |
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease |
|
|
Interventional |
Phase 4 |
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Summary of Adverse Events (AEs)
- Change From Baseline in the Mini-Mental State Examination (MMSE) Score
- Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores
|
171 |
All |
45 Years to 90 Years (Adult, Senior) |
NCT02097056 |
ART-M082-401 |
SAVE |
February 2014 |
May 2015 |
May 2015 |
March 26, 2014 |
June 27, 2016 |
June 27, 2016 |
- Chungju, Chungcheongbuk-do, Korea, Republic of
- Ansan, Gyeonggi-do, Korea, Republic of
- Buchoen, Gyeonggi-do, Korea, Republic of
- (and 10 more...)
|
| 10 |
NCT02158910 |
Completed |
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients |
|
|
Observational |
|
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
|
2231 |
All |
Child, Adult, Senior |
NCT02158910 |
ART-M082-601 |
AID |
March 2015 |
June 2016 |
June 2016 |
June 9, 2014 |
March 7, 2017 |
|
- Busan, Korea, Republic of
- Chungcheongbuk-do, Korea, Republic of
- Chungcheongnam-do, Korea, Republic of
- (and 10 more...)
|
| 11 |
NCT02946710 |
Completed |
P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid |
|
- Biological: cerebrospinal fluid
|
Observational |
|
- University Hospital, Toulouse
|
Other |
- Observational Model: Other
- Time Perspective: Retrospective
|
- Concentration of p75NTR-ECD total
- Concentration of p75NTR-ECD bound to Aβ1-40 and Aβ1-42
- expression of p75NTR-ECD between patient groups
|
120 |
All |
40 Years and older (Adult, Senior) |
NCT02946710 |
14 7317 02 |
P75NTR-MND |
December 2014 |
June 2017 |
December 2017 |
October 27, 2016 |
April 3, 2018 |
|
- University Hospital of Toulouse
Toulouse, France
|
| 12 |
NCT02220738 |
Terminated |
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors |
|
- Drug: ABT-957
- Other: Placebo for ABT-957
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pharmacokinetic evaluation of the two ABT-957 diastereomers
- Number of subjects with adverse events
|
19 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT02220738 |
M13-334 |
|
September 2014 |
March 2016 |
March 2016 |
August 20, 2014 |
June 16, 2016 |
|
- Site Reference ID/Investigator# 129545
Glendale, California, United States - Site Reference ID/Investigator# 129435
Orlando, Florida, United States - Site Reference ID/Investigator# 129641
New York, New York, United States - Site Reference ID/Investigator# 144825
Salt Lake City, Utah, United States
|
| 13 |
NCT02005380 |
Completed |
Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation |
|
- Other: Text-based task
- Other: Graphic-based Task
|
Observational |
|
- German-Jordanian University
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- NASA Task Load Index Measure
- Test Score
|
20 |
All |
60 Years and older (Adult, Senior) |
NCT02005380 |
GJU001 |
|
November 2013 |
November 2013 |
November 2013 |
December 9, 2013 |
December 9, 2013 |
|
- Darat Samir Shamma
Amman, Jordan
|
| 14 |
NCT02899091 |
Not yet recruiting |
Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease |
|
- Biological: CB-AC-02
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Adverse Events
- Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score
- Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score
- (and 11 more...)
|
24 |
All |
50 Years and older (Adult, Senior) |
NCT02899091 |
CHA-PAD-101 |
|
September 2016 |
March 2018 |
June 2018 |
September 14, 2016 |
September 14, 2016 |
|
- Bundang Medical Center
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
| 15 |
NCT01078168 |
Completed
Has Results |
Alzheimer`s Disease Acitretin Medication |
|
- Drug: Acitretin
- Drug: Placebo
|
Interventional |
Phase 2 |
- K. Lieb
- Alzheimer Forschungsinitiative e.V. (AFI)
- Johannes Gutenberg University Mainz
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT01078168 |
ADAM
2009-011881-27 |
ADAM |
March 2010 |
January 2013 |
May 2013 |
March 2, 2010 |
February 2, 2018 |
February 2, 2018 |
- Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz
Mainz, Rheinland-Pfalz, Germany - Universität Rostock
Rostock, Germany
|
| 16 |
NCT03408041 |
Completed |
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters |
|
- Other: Medical file data extraction
|
Observational |
|
- Murielle Surquin
- Brugmann University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Age
- Sex
- Ethnic origin
- (and 2 more...)
|
129 |
All |
Child, Adult, Senior |
NCT03408041 |
CHUB-parameters Alzheimer |
|
May 1, 2016 |
October 1, 2017 |
October 1, 2017 |
January 23, 2018 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium
|
| 17 |
NCT01689948 |
Terminated |
Alzheimer Disease : Rehabilitation's Intervention at Home |
|
- Behavioral: Home rehabilitation therapy
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Evaluation of the mean scores of Instrumental Activities of Daily Living (IADL)
- Evaluation of the mean scores of Neuro Psychiatric Inventory (NPI)
- Evaluation of the mean scores of Zarit's scale (caregiver burden)
- (and 3 more...)
|
17 |
All |
65 Years and older (Adult, Senior) |
NCT01689948 |
RC12_0080 |
pré MATAPA |
October 2012 |
May 2014 |
September 2014 |
September 21, 2012 |
October 15, 2014 |
|
- Bellier Hospital, CHU of Nantes
Nantes, France
|
| 18 |
NCT01908010 |
Completed |
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors |
|
- Drug: ABT-354
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Vital signs
- ECG (electrocardiogram)
- Neurological exam
- (and 4 more...)
|
20 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01908010 |
M13-080 |
|
July 2013 |
November 2013 |
November 2013 |
July 25, 2013 |
December 11, 2013 |
|
- Site Reference ID/Investigator# 106999
Miami, Florida, United States - Site Reference ID/Investigator# 106998
Orlando, Florida, United States - Site Reference ID/Investigator# 107000
Overland Park, Kansas, United States
|
| 19 |
NCT01782742 |
Completed
Has Results |
Bexarotene Amyloid Treatment for Alzheimer's Disease |
|
- Drug: Bexarotene
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain
- Primary Outcome by Genotype (ALL SUBJECTS)
- Primary Outcome by Genotype (NON ApoE4 CARRIERS)
- (and 12 more...)
|
20 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT01782742 |
CCF-IRB 12-783 |
BEAT-AD |
February 2013 |
August 2014 |
December 2014 |
February 4, 2013 |
February 12, 2016 |
February 12, 2016 |
- Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada, United States
|
| 20 |
NCT01715350 |
Completed |
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease |
|
|
Interventional |
Phase 2 |
- Purimed Co., Ltd.
- ADM Korea Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ADAS-cog
- CDR
- K-IADL
- (and 4 more...)
|
151 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01715350 |
PM012-P2 |
ADD |
May 2012 |
September 2014 |
June 2015 |
October 26, 2012 |
April 18, 2016 |
|
- Kyung Hee University Oriental Medicine Hospital
Seoul, Dongdaemun-gu, Korea, Republic of - National Health Insurance Corporation Ilsan Hospital
Goyang, Ilsandong-gu, Korea, Republic of - The Catholic University of Korea, St. Vincent's Hospital
Suwon, Paldal-gu, Korea, Republic of - The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seocho-gu, Korea, Republic of
|
| 21 |
NCT02565511 |
Recruiting |
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
|
Interventional |
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Banner Alzheimer's Institute
- National Institute on Aging (NIA)
- (and 3 more...)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 7 more...)
|
1340 |
All |
60 Years to 75 Years (Adult, Senior) |
NCT02565511 |
CAPI015A2201J
2015-002715-15
1UF1AG046150-01 |
Generation S1 |
November 30, 2015 |
August 30, 2024 |
September 2, 2024 |
October 1, 2015 |
April 18, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Banner Sun City Research Institute
Sun City, Arizona, United States - (and 73 more...)
|
| 22 |
NCT01703117 |
Recruiting |
Riluzole in Mild Alzheimer's Disease |
|
- Drug: Riluzole
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Imaging Biomarkers N-acetylaspartate (NAA) and FDG-PET values in regions of interest
- Cognitive function (neuropsychological tests); Glutamate levels obtained through MRS
|
48 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01703117 |
APE-0792 |
|
November 2013 |
November 2019 |
November 2019 |
October 10, 2012 |
September 25, 2017 |
|
- The Rockefeller University
New York, New York, United States
|
| 23 |
NCT01883648 |
Terminated |
Study to Evaluate Coconut Oil for Alzheimer's Disease |
|
- Drug: Coconut Oil Beverage
- Other: Placebo Beverage
|
Interventional |
Phase 2
Phase 3 |
- University of South Florida
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale
- (and 4 more...)
|
21 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01883648 |
Byrd AD-001 |
|
June 2013 |
February 1, 2017 |
February 1, 2017 |
June 21, 2013 |
April 28, 2017 |
|
- USF Health Byrd Alzheimer's Institute
Tampa, Florida, United States
|
| 24 |
NCT01428453 |
Completed |
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease |
|
- Drug: 250mg rilapladib
- Drug: placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in CSF Abeta42, Abeta40, Abeta42/ Abeta40 ratio
- Change from baseline in CSF tau and P-tau
- Change from baseline in working memory/executive function composite score
- (and 6 more...)
|
124 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT01428453 |
114458 |
|
October 2011 |
February 2013 |
February 2013 |
September 5, 2011 |
May 13, 2015 |
|
- GSK Investigational Site
Sofia, Bulgaria - GSK Investigational Site
Sofia, Bulgaria - GSK Investigational Site
Toronto, Ontario, Canada - (and 27 more...)
|
| 25 |
NCT01608061 |
Active, not recruiting |
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease |
|
- Device: DBS-f on
- Device: DBS-f off
|
Interventional |
Not Applicable |
- Functional Neuromodulation Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The study will assess the acute and long-term safety of the system. A detailed assessment of all device and/or therapy related adverse events will be conducted.
- Efficacy outcomes include: improvement in ADAS-cog 13 at twelve months, improvement in the CDR and changes in glucose metabolism measured by FDG-PET at twelve months
|
50 |
All |
45 Years to 85 Years (Adult, Senior) |
NCT01608061 |
FNMI-001 |
ADvance |
May 2012 |
June 2015 |
September 2018 |
May 30, 2012 |
February 16, 2017 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Banner Research Institute at Sun City
Sun City, Arizona, United States - University of Florida at Gainesville
Gainesville, Florida, United States - (and 4 more...)
|
| 26 |
NCT03055741 |
Recruiting |
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil |
- Mild-moderate Alzheimer's Disease
|
- Drug: Donepezil
- Drug: DHP1401
- Drug: Placebo
|
Interventional |
Phase 2 |
- Daehwa Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)
- Clinical Dementia Rating Sum of Box Korean version(CDR-SB)
- Neuropsychiatric Inventory-Q Korean version(NPI-Q)
- (and 3 more...)
|
180 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03055741 |
1401CS-2 |
|
December 28, 2016 |
September 2018 |
September 2018 |
February 16, 2017 |
December 4, 2017 |
|
- The Catholic University of Korea, Bucheon, ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, Korea, Republic of - Myongji Hospital
Goyang-si, Gyeonggi-do, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of - (and 8 more...)
|
| 27 |
NCT02079909 |
Completed |
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) |
|
- Drug: T-817MA-H
- Drug: T-817MA-L
- Drug: Placebo
|
Interventional |
Phase 2 |
- Toyama Chemical Co., Ltd.
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.
- Clinical Safety
- Efficacy
|
484 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02079909 |
T817MAUS202 |
|
March 2014 |
May 5, 2017 |
May 5, 2017 |
March 6, 2014 |
May 17, 2017 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Banner Sun Health Research Institute
Sun City, Arizona, United States - University of Arizona Health Sciences Center
Tucson, Arizona, United States - (and 47 more...)
|
| 28 |
NCT01624389 |
Unknown † |
Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study |
|
|
Interventional |
Not Applicable |
- Chang Gung Memorial Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Rate of conversion from NC, EMCI, LMCI to AD.
|
200 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01624389 |
101-1074A1 |
Alzheimer's |
January 2012 |
January 2015 |
January 2015 |
June 20, 2012 |
June 20, 2012 |
|
- Tzu-Chen-Yen
Taoyuan, Taiwan
|
| 29 |
NCT01354444 |
Completed
Has Results |
Trial of Carvedilol in Alzheimer's Disease |
|
- Drug: Carvedilol
- Drug: Placebo
|
Interventional |
Phase 4 |
- Johns Hopkins University
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hopkins Verbal Learning Test (HVLT) Scores at Baseline, 3, and 6 Months
- Effect of Carvedilol Treatment in Cerebrospinal Fluid (CSF) Levels of Amyloid-beta Oligomers
|
29 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT01354444 |
NA_00035546 |
|
June 2011 |
December 2016 |
January 2017 |
May 16, 2011 |
February 6, 2018 |
February 6, 2018 |
- Johns Hopkins School of Medicine Bayview Campus
Baltimore, Maryland, United States
|
| 30 |
NCT03507790 |
Not yet recruiting
New |
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. |
- Mild to Moderate Alzheimer's Disease
|
- Drug: CT1812
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To assess the pharmacodynamic effect of CT1812 on CSF biomarker
|
24 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT03507790 |
COG0201 |
|
May 31, 2018 |
November 30, 2019 |
December 31, 2019 |
April 25, 2018 |
April 25, 2018 |
|
|
| 31 |
NCT03186989 |
Recruiting |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease |
|
- Drug: IONIS MAPTRx
- Other: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Incidence and severity of adverse events that are related to treatment with IONIS MAPTRx
- Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (trough concentration)
- Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (maximum observed drug concentration or Cmax)
- (and 3 more...)
|
44 |
All |
50 Years to 74 Years (Adult, Senior) |
NCT03186989 |
ISIS 814907-CS1 |
|
June 5, 2017 |
January 31, 2020 |
February 29, 2020 |
June 14, 2017 |
February 21, 2018 |
|
- Montreal Neurological Hospital
Montréal, Canada - Clinical Research Services Turku CRST
Turku, Finland - Charite - Universitaetsmedizin Berlin Campus Mitte
Berlin, Germany - (and 9 more...)
|
| 32 |
NCT01254448 |
Completed |
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease |
|
- Drug: TC-5619
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Diagnostic
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Pharmacokinetic profiles
- Markers of inflammation in cerebrospinal fluid
- Markers of inflammation in plasma
|
38 |
All |
55 Years to 80 Years (Adult, Senior) |
NCT01254448 |
TC-5619-238-CLP-003 |
|
September 2010 |
March 2011 |
May 2011 |
December 6, 2010 |
September 4, 2013 |
|
- Collaborative Neuroscience Network
Long Beach, California, United States - San Francisco Clinical Research Center
San Francisco, California, United States - MD Clinical
Hallandale Beach, Florida, United States - (and 7 more...)
|
| 33 |
NCT03269149 |
Recruiting |
Tango for Alzheimer's Disease Patients' Caregivers |
|
- Other: Adapted Tango Dance
- Behavioral: Educational lectures
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in interleukin-7
- Change in interleukin-8
- Change in interleukin-9
- (and 25 more...)
|
60 |
Female |
45 Years to 65 Years (Adult) |
NCT03269149 |
IRB00097348 |
|
September 19, 2017 |
July 31, 2018 |
July 31, 2018 |
August 31, 2017 |
September 25, 2017 |
|
- Atlanta VA Medical Center, Emory University, Executive Park, Wesley Woods
Atlanta, Georgia, United States
|
| 34 |
NCT03290274 |
Recruiting |
Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease |
|
- Device: Deep brain stimulation (fornix)
- Device: Deep brain stimulation (Basal nucleus of Meynert)
|
Interventional |
Not Applicable |
- Hospital San Carlos, Madrid
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
6 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03290274 |
ECP-EA |
ECP-EA |
March 1, 2017 |
December 1, 2019 |
December 1, 2019 |
September 21, 2017 |
September 21, 2017 |
|
- Hospital Clinico San Carlos
Madrid, Spain
|
| 35 |
NCT01966666 |
Active, not recruiting |
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease |
|
- Drug: TPI-287 2 mg/m2
- Drug: TPI-287 6.3 mg/m2
- Drug: TPI-287 20 mg/m2
- Drug: Placebo
|
Interventional |
Phase 1 |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
|
- Maximum tolerated dose of TPI-287
- TPI-287 levels in blood plasma and cerebrospinal fluid
|
33 |
All |
50 Years to 82 Years (Adult, Senior) |
NCT01966666 |
TPI287-AD-001 |
|
November 2013 |
May 2017 |
November 2017 |
October 21, 2013 |
December 7, 2016 |
|
- UCSF Memory and Aging Center
San Francisco, California, United States
|
| 36 |
NCT02586909 |
Terminated |
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension |
|
- Drug: RVT-101 35 mg tablets
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of adverse events (AEs) and or reported changes in physical examinations, vital signs measurements, electrocardiograms (ECGs), routine laboratory assessments
|
1100 |
All |
50 Years to 86 Years (Adult, Senior) |
NCT02586909 |
RVT-101-3002 |
|
April 2016 |
March 2018 |
March 2018 |
October 27, 2015 |
March 20, 2018 |
|
- US112
Phoenix, Arizona, United States - US220
Tucson, Arizona, United States - US096
Rancho Mirage, California, United States - (and 166 more...)
|
| 37 |
NCT02615002 |
Recruiting |
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) |
|
- Drug: Piromelatine
- Drug: Placebo
|
Interventional |
Phase 2 |
- Neurim Pharmaceuticals Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Computerized neuropsychological test battery (cNTB)
- Change from baseline in Global Impression of Change (CGIC)
- Change from baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS-MCI-ADL)
- (and 2 more...)
|
500 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT02615002 |
NeuP11-AD2 |
|
November 2015 |
April 2019 |
April 2019 |
November 25, 2015 |
April 11, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Territory Neurology & Research Institute
Tucson, Arizona, United States - Citrials Inc
Bellflower, California, United States - (and 56 more...)
|
| 38 |
NCT02292238 |
Recruiting |
Benfotiamine in Alzheimer's Disease: A Pilot Study |
|
|
Interventional |
Phase 2 |
- Burke Medical Research Institute
- Burke Rehabilitation Hospital
- Columbia University
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ADAS-cog as the primary clinical outcome
- Brain glucose utilization
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- (and 3 more...)
|
76 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02292238 |
BRC-451
1R01AG043679-01A1 |
Benfotiamine |
November 2014 |
November 2018 |
November 2019 |
November 17, 2014 |
January 17, 2018 |
|
- Burke
White Plains, New York, United States
|
| 39 |
NCT03472183 |
Not yet recruiting |
Exploration of the Enteric Nervous System in Alzheimer Disease |
|
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease
- Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
|
30 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03472183 |
RC17_0252 |
SYNEMA |
March 25, 2018 |
November 25, 2020 |
November 25, 2020 |
March 21, 2018 |
March 21, 2018 |
|
|
| 40 |
NCT01935024 |
Recruiting |
Benefits of Exercise in Alzheimer's Disease |
|
- Other: Personalized Exercise Regimen
|
Interventional |
Not Applicable |
- University Health Network, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Neuropsychological Test Battery
|
60 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT01935024 |
12-5749-AE |
|
August 2013 |
April 2018 |
April 2018 |
September 4, 2013 |
October 26, 2017 |
|
- Toronto Western Hospital, WW5-449
Toronto, Ontario, Canada
|
| 41 |
NCT01767311 |
Active, not recruiting |
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease |
|
- Drug: BAN2401 2.5 mg/kg
- Drug: BAN2401 5.0 mg/kg
- Drug: BAN2401 10 mg/kg
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Core Study: Change from Baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months
- Core Study and Extension Phase: Safety will be assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs)
- Core Study: Change from baseline in the ADCOMS at 18 months
- (and 3 more...)
|
856 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT01767311 |
BAN2401-G000-201
2012-002843-11 |
|
December 2012 |
July 2018 |
November 2018 |
January 14, 2013 |
February 15, 2018 |
|
- Facility #1
Birmingham, Alabama, United States - Facility #1
Phoenix, Arizona, United States - Facility #1
Tucson, Arizona, United States - (and 115 more...)
|
| 42 |
NCT03352557 |
Recruiting |
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease |
|
- Drug: BIIB092
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Percentage of Participants With Abnormal Laboratory Safety Assessments
- Percentage of Participants With Changes From Baseline Over Time in Laboratory Safety Assessments
- (and 7 more...)
|
528 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03352557 |
251AD201
2017-002901-37 |
TANGO |
April 20, 2018 |
July 21, 2021 |
September 8, 2021 |
November 24, 2017 |
April 11, 2018 |
|
- Xenoscience Inc
Phoenix, Arizona, United States - Associated Neurologists of Southern Connecticut, P.C.
Fairfield, Connecticut, United States - JEM Research Institute
Atlantis, Florida, United States - (and 3 more...)
|
| 43 |
NCT00870519 |
Terminated |
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects |
|
- Drug: I-123-MNI-168
- Drug: 123-I MNI-168
|
Interventional |
Phase 1 |
- Institute for Neurodegenerative Disorders
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain,
- To acquire initial safety data following injection of (123I) MNI-168.
|
2 |
All |
50 Years and older (Adult, Senior) |
NCT00870519 |
MNI-168-01 |
|
January 2009 |
January 2010 |
January 2011 |
March 27, 2009 |
February 25, 2011 |
|
- Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
|
| 44 |
NCT01569516 |
Unknown † |
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease |
|
- Drug: Octohydroaminoacridine Succinate Tablets
- Drug: Octohydroaminoacridine succinate Tablets
- Drug: Placebo
|
Interventional |
Phase 2 |
- Changchun Huayang High-tech Co., Ltd
- Beijing Bionovo Medicine Development Co., Ltd.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale
- Clinician's Interview Based Impression of Change, plus caregiver input
- Activities of Daily Living:Activities of Daily Living Scale（ADL)
- Mental behavior: neuropsychiatric questionnaire (NPI)
|
288 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01569516 |
CCHY2010L00161-HPAD2 |
|
June 2011 |
July 2012 |
October 2012 |
April 3, 2012 |
April 9, 2012 |
|
- Guangzhou Brain Hospital
Guangzhou, Guangdong, China - Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China - Hebei mental health center
Baoding, Hebei, China - (and 10 more...)
|
| 45 |
NCT02916056 |
Enrolling by invitation |
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) |
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events
- Clinical Safety Laboratory Tests
- Electrocardiogram
- (and 14 more...)
|
640 |
All |
50 Years and older (Adult, Senior) |
NCT02916056 |
TTP488-303 |
|
December 2016 |
November 2020 |
November 2020 |
September 27, 2016 |
March 15, 2018 |
|
- Phoenix, Arizona, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- (and 68 more...)
|
| 46 |
NCT01555827 |
Completed |
Retinal Neurodegenerative Signs in Alzheimer's Diseases |
|
- Other: Ophthalmological examination & Questionnaire
|
Interventional |
Not Applicable |
- University Hospital, Bordeaux
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- RNFL thickness measured on a peri-papillary scan of SD-OCT examination.
- Glaucomatous optic nerve damage observed on colour photographs (cup/disc ratio)
- Retinal microvascular abnormalities (microaneurysms, micro-hemorrhage, cotton wool spots, arteriovenous nicking), observed on retinal colour photography
- (and 7 more...)
|
200 |
All |
50 Years and older (Adult, Senior) |
NCT01555827 |
CHUBX2011/19 |
SIGNAL |
March 12, 2012 |
June 7, 2014 |
June 7, 2014 |
March 15, 2012 |
November 13, 2017 |
|
- CHU Bordeaux - hôpital Pellegrin
Bordeaux, France
|
| 47 |
NCT02406027 |
Active, not recruiting |
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum |
|
- Drug: JNJ-54861911, 10 mg
- Drug: JNJ-54861911, 25 mg
- Drug: Placebo
- Drug: JNJ-54861911, 5 mg
|
Interventional |
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels
- Percent Change From Baseline in Plasma ABeta Levels 1-37, 1-38, 1-40, and 1-42
- (and 3 more...)
|
90 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02406027 |
CR106978
54861911ALZ2004
2014-004274-41 |
|
July 2, 2015 |
October 13, 2022 |
October 13, 2022 |
April 1, 2015 |
January 30, 2018 |
|
- Gent, Belgium
- Hoboken, Belgium
- Montpellier Cedex 5, France
- (and 14 more...)
|
| 48 |
NCT00762411 |
Completed
Has Results |
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo |
|
- Drug: LY450139
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks
- Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 16 Weeks After Cessation of Study Drug
- Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 76 Weeks
- (and 26 more...)
|
1111 |
All |
55 Years and older (Adult, Senior) |
NCT00762411 |
11271
H6L-MC-LFBC |
IDENTITY-2 |
September 2008 |
April 2011 |
April 2011 |
September 30, 2008 |
February 16, 2015 |
September 25, 2014 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Costa Mesa, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
La Jolla, California, United States - (and 88 more...)
|
| 49 |
NCT02260674 |
Completed |
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease |
|
- Drug: JNJ-54861911, 10 milligram (mg)
- Drug: JNJ-54861911, 50 mg
- Drug: Placebo
|
Interventional |
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Relationship Between Dose and Exposure of JNJ-54861911 With Safety
- Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels
- (and 5 more...)
|
114 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02260674 |
CR105240
54861911ALZ2002
2014-002159-24 |
|
November 2014 |
June 2016 |
June 2016 |
October 9, 2014 |
March 3, 2017 |
|
- Gent, Belgium
- Hoboken, Belgium
- Montpellier Cedex 5, France
- (and 16 more...)
|
| 50 |
NCT03417986 |
Recruiting |
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efflux of Amyloid beta peptides (Group mean changes from baseline)
- Scores obtained in psychometric tests [Cognition]
- Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]
- Cerebrospinal fluid (CSF) levels of Tau
|
100 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT03417986 |
IMU-AD-001 |
drainAD |
November 24, 2017 |
July 2021 |
July 2021 |
January 31, 2018 |
January 31, 2018 |
|
- Klinik für Psychiatrie und Psychotherapie Universitätsmedizin Göttingen
Göttingen, Germany - Zentralinstitut für seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg,
Mannheim, Germany
|
Create an RSS feed from your search for:
Download the search results for: